Home

Our vision is to be the global leader in prescription cannabinoid medicines, developing and providing pharmaceutical products which address clear unmet needs.

Justin Gover
Chief Executive Officer

Recent News

group of professional people
Mar 22, 2017
GREENWICH Biosciences is growing. We are excited to announce that GREENWICH Biosciences, the U.S. subsidiary of GW Pharmaceuticals, has moved in order to accommodate our growing U.S. team. Our new space in the Ocean Terrace Corporate Center quadruples our prior footprint in Carlsbad with over 21,000 square feet and capacity for 125 people.

Pharmaceutical Development Pipeline

Pharmaceutical Development Pipeline

  • Unpartnered
  • Partnered
  • Pre-Clinic
  • Phase 1
  • Phase 2
  • Phase 3
  • Submit
  • Approved

Epilepsy

CBD Oral Solution
Dravet Syndrome
2 Phase 3 Trials
Completed Phase 3
CBD Oral Solution
Lennox-Gastaut Syndrome
Completed Phase 3
CBD Oral Solution
Tuberous Sclerosis Complex
Phase 3 Trial Recruiting
Completed Phase 2
CBD Oral Solution
Infantile Spasms
Phase 2 Trial Underway
Phase 2
CBD IV
Neonatal Hypoxic-ischemic Encephalopathy
Pre-Clinic